- Home
- GVA vs ZLAB Comparison
GVA vs ZLAB Comparison
Compare GVA & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GVA
- ZLAB
- Stock Information
- Founded
- GVA 1922
- ZLAB 2013
- Country
- GVA United States
- ZLAB China
- Employees
- GVA N/A
- ZLAB N/A
- Industry
- GVA Military/Government/Technical
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- GVA Industrials
- ZLAB Health Care
- Exchange
- GVA Nasdaq
- ZLAB Nasdaq
- Market Cap
- GVA 3.8B
- ZLAB 3.0B
- IPO Year
- GVA 1990
- ZLAB 2017
- Fundamental
- Price
- GVA $98.19
- ZLAB $25.70
- Analyst Decision
- GVA Hold
- ZLAB Strong Buy
- Analyst Count
- GVA 2
- ZLAB 4
- Target Price
- GVA $67.00
- ZLAB $52.50
- AVG Volume (30 Days)
- GVA 709.8K
- ZLAB 1.4M
- Earning Date
- GVA 10-31-2024
- ZLAB 11-12-2024
- Dividend Yield
- GVA 0.53%
- ZLAB N/A
- EPS Growth
- GVA 144.49
- ZLAB N/A
- EPS
- GVA 2.18
- ZLAB N/A
- Revenue
- GVA $3,963,969,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- GVA $14.59
- ZLAB $48.50
- Revenue Next Year
- GVA $6.86
- ZLAB $47.37
- P/E Ratio
- GVA $45.32
- ZLAB N/A
- Revenue Growth
- GVA 17.81
- ZLAB 35.01
- 52 Week Low
- GVA $43.92
- ZLAB $13.48
- 52 Week High
- GVA $99.32
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- GVA 76.73
- ZLAB 40.72
- Support Level
- GVA $95.30
- ZLAB $24.85
- Resistance Level
- GVA $98.56
- ZLAB $26.77
- Average True Range (ATR)
- GVA 2.70
- ZLAB 1.53
- MACD
- GVA 0.07
- ZLAB -0.80
- Stochastic Oscillator
- GVA 91.53
- ZLAB 11.14
About GVA Granite Construction Incorporated
Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. It focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, with the remainder derived from its Materials segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.